NGL FINECHEM
Back to Balance Sheet
|
NGL FINECHEM Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹69 Cr | ₹41 Cr | ₹6.32 Cr | ₹6.24 Cr | ₹8.06 Cr |
What is the latest Total Non-Current Liabilities ratio of NGL FINECHEM ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2026 | ₹69 Cr |
| Mar2025 | ₹41 Cr |
| Mar2024 | ₹6.32 Cr |
| Mar2023 | ₹6.24 Cr |
| Mar2022 | ₹8.06 Cr |
How is Total Non-Current Liabilities of NGL FINECHEM Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹69 Cr | 67.27 | |
| Mar2025 | ₹41 Cr | 549.52 | |
| Mar2024 | ₹6.32 Cr | 1.27 | |
| Mar2023 | ₹6.24 Cr | -22.60 | |
| Mar2022 | ₹8.06 Cr | - | |
Compare Total Non-Current Liabilities of peers of NGL FINECHEM
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NGL FINECHEM | ₹1,816.4 Cr | -15.3% | -6.5% | 180.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹451,675.0 Cr | -3% | -2.6% | 21.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹225,516.0 Cr | -0.5% | 17% | 43.8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹186,190.0 Cr | 0.6% | 2.7% | 35.5% | Stock Analytics | |
| CIPLA | ₹115,523.0 Cr | -2.2% | 0.8% | -2.4% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,493.4 Cr | -1.1% | -1.6% | -0.8% | Stock Analytics | |
NGL FINECHEM Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NGL FINECHEM | -15.3% |
-6.5% |
180.8% |
| SENSEX | -1% |
0.7% |
-3.6% |
You may also like the below Video Courses